CMRA - Comera Life Sciences Holdings, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Comera Life Sciences Holdings, Inc.

12 Gill Street
Suite 4650
Woburn, MA 01801
United States

Full-time employees12

Key executives

NameTitlePayExercisedYear born
Mr. Jeffrey S. HackmanChairman, Pres & CEO400kN/A1961
Mr. Michael G. Campbell CPAExec. VP & CFO269.11kN/A1969
Dr. Neal I. Muni M.D., MSPHExec. VP & COO350kN/A1975
Dr. David Soane Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Robert P. Mahoney Ph.D.Chief Scientific OfficerN/AN/A1964
Ms. Janice Marie McCourt B.S., CLP, M.B.A., R.Ph.Chief Bus. OfficerN/AN/A1962
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Corporate governance

Comera Life Sciences Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.